☰

Raymond A. Pagliarini, Ph.D. - Publications

Affiliations: 
Novartis, Basel, Basel-Stadt, France 
Tree Info Grants Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, Rodrigues S, Cizmecioglu O, Jia S, Korpal M, Korn JM, Wang Z, Schmit F, Jiang L, Pagliarini R, et al. Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Molecular Cancer Research : McR. PMID 35105671 DOI: 10.1158/1541-7786.MCR-21-0322  0.323
2020 Ye LF, Reznik E, Korn JM, Lin F, Yang G, Malesky K, Gao H, Loo A, Pagliarini R, Mikkelsen T, Lo DC, deCarvalho AC, Stockwell BR. Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery. Oncotarget. 11: 443-451. PMID 32064048 DOI: 10.18632/Oncotarget.27457  0.386
2019 Li H, Ning S, Ghandi M, Kryukov GV, Gopal S, Deik A, Souza A, Pierce K, Keskula P, Hernandez D, Ann J, Shkoza D, Apfel V, Zou Y, Vazquez F, ... ... Pagliarini RA, et al. The landscape of cancer cell line metabolism. Nature Medicine. 25: 850-860. PMID 31068703 DOI: 10.1038/S41591-019-0404-8  0.374
2018 Liu H, Golji J, Brodeur LK, Chung FS, Chen JT, deBeaumont RS, Bullock CP, Jones MD, Kerr G, Li L, Rakiec DP, Schlabach MR, Sovath S, Growney JD, Pagliarini RA, et al. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nature Medicine. PMID 30559422 DOI: 10.1038/S41591-018-0302-5  0.453
2018 Zhao Q, Manning JR, Sutton J, Costales A, Sendzik M, Shafer CM, Levell JR, Liu G, Caferro T, Cho YS, Palermo M, Chenail G, Dooley J, Villalba B, Farsidjani A, ... ... Pagliarini R, et al. Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors. Acs Medicinal Chemistry Letters. 9: 746-751. PMID 30034612 DOI: 10.1021/Acsmedchemlett.8B00182  0.402
2017 Cho YS, Levell JR, Liu G, Caferro T, Sutton J, Shafer CM, Costales A, Manning JR, Zhao Q, Sendzik M, Shultz M, Chenail G, Dooley J, Villalba B, Farsidjani A, ... ... Pagliarini R, et al. Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. Acs Medicinal Chemistry Letters. 8: 1116-1121. PMID 29057061 DOI: 10.1021/Acsmedchemlett.7B00342  0.405
2017 McDonald ER, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, Belur D, Castelletti D, Frias E, Gampa K, Golji J, Kao I, Li L, Megel P, Perkins TA, ... ... Pagliarini RA, et al. Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell. 170: 577-592.e10. PMID 28753431 DOI: 10.1016/J.Cell.2017.07.005  0.434
2017 Levell JR, Caferro T, Chenail G, Dix I, Dooley J, Firestone B, Fortin PD, Giraldes J, Gould T, Growney JD, Jones MD, Kulathila R, Lin F, Liu G, Mueller A, ... ... Pagliarini R, et al. Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1. Acs Medicinal Chemistry Letters. 8: 151-156. PMID 28197303 DOI: 10.1021/Acsmedchemlett.6B00334  0.308
2017 Xie X, Baird D, Bowen K, Capka V, Chen J, Chenail G, Cho Y, Dooley J, Farsidjani A, Fortin P, Kohls D, Kulathila R, Lin F, McKay D, Rodrigues L, ... ... Pagliarini RA, et al. Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity. Structure (London, England : 1993). PMID 28132785 DOI: 10.1016/J.Str.2016.12.017  0.366
2016 Mounir Z, Korn JM, Westerling T, Lin F, Kirby CA, Schirle M, McAllister G, Hoffman G, Ramadan N, Hartung A, Feng Y, Kipp DR, Quinn C, Fodor M, Baird J, ... ... Pagliarini RA, et al. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor. Elife. 5. PMID 27183006 DOI: 10.7554/Elife.13964  0.346
2016 Mavrakis KJ, McDonald ER, Schlabach MR, Billy E, Hoffman GR, deWeck A, Ruddy DA, Venkatesan K, Yu J, McAllister G, Stump M, deBeaumont R, Ho S, Yue Y, Liu Y, ... ... Pagliarini R, et al. Disordered methionine metabolism in MTAP/CDKN2A deleted cancers leads to dependence on PRMT5. Science (New York, N.Y.). PMID 26912361 DOI: 10.1126/Science.Aad5944  0.477
2016 DiNardo CD, Schimmer AD, Yee KW, Hochhaus A, Kraemer A, Carvajal RD, Janku F, Bedard P, Carpio C, Wick A, Schwartz GK, Schöffski P, Wen P, van den Bent MJ, Rosenthal M, ... ... Pagliarini R, et al. A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations Blood. 128: 1073-1073. DOI: 10.1182/Blood.V128.22.1073.1073  0.303
2016 Mavrakis K, McDonald ER, Schlabach MR, Billy E, Hoffman GR, deWeck A, Ruddy DA, Venkatesan K, McAllister G, deBeaumont R, Ho S, Liu Y, Yan-Neale Y, Yang G, Lin F, ... ... Pagliarini R, et al. Abstract LB-017: Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to marked dependence on PRMT5 Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-017  0.405
2015 Pagliarini R, Shao W, Sellers WR. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. Embo Reports. 16: 280-96. PMID 25680965 DOI: 10.15252/Embr.201439949  0.391
2015 Mounir Z, Lin F, Lin VG, Korn JM, Yu Y, Valdez R, Aina OH, Buchwalter G, Jaffe AB, Korpal M, Zhu P, Brown M, Cardiff RD, Rocnik JL, Yang Y, ... Pagliarini R, et al. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene. 34: 3815-25. PMID 25263440 DOI: 10.1038/Onc.2014.308  0.386
2014 Chen Y, Chen J, Yu J, Yang G, Temple E, Harbinski F, Gao H, Wilson C, Pagliarini R, Zhou W. Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition. The Journal of Biological Chemistry. 289: 18914-27. PMID 24831003 DOI: 10.1074/Jbc.M114.574053  0.378
2014 Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang X, Slocum KL, Pu M, Lin F, Vickers C, Joud-Caldwell C, Chung F, Yin H, Handly ED, Straub C, ... ... Pagliarini R, et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Research. 74: 3317-31. PMID 24755473 DOI: 10.1158/0008-5472.Can-14-0772-T  0.369
2014 Pop MS, Stransky N, Garvie CW, Theurillat JP, Hartman EC, Lewis TA, Zhong C, Culyba EK, Lin F, Daniels DS, Pagliarini R, Ronco L, Koehler AN, Garraway LA. A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein. Molecular Cancer Therapeutics. 13: 1492-502. PMID 24737027 DOI: 10.1158/1535-7163.Mct-13-0689  0.387
2014 Grassian AR, Pagliarini R, Chiang DY. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. Current Opinion in Gastroenterology. 30: 295-302. PMID 24569570 DOI: 10.1097/Mog.0000000000000050  0.336
2014 Grassian AR, Parker S, Davidson S, Divakaruni A, Green C, Zhang X, Slocum K, Pu M, Lin F, Vickers C, Joud-Caldwell C, Chung F, Yin H, Handly E, Straub C, ... ... Pagliarini R, et al. Abstract LB-139: IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-139  0.374
2014 Chen Y, Chen J, Loo A, Mclaughlin M, Pagliarini R, Zhou W. Abstract 682: Identification of HSP90 inhibitor sensitizers through pooled RNA interference screen Cancer Research. 74: 682-682. DOI: 10.1158/1538-7445.Am2014-682  0.408
2014 Pop M, Stransky N, Garvie C, Theurillat J, Lewis T, Zhong C, Culyba E, Lin F, Daniels D, Pagliarini R, Ronco L, Koehler A, Garraway L. Abstract 2519: A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein Cancer Research. 74: 2519-2519. DOI: 10.1158/1538-7445.Am2014-2519  0.384
2013 Chen J, Chung F, Yang G, Pu M, Gao H, Jiang W, Yin H, Capka V, Kasibhatla S, Laffitte B, Jaeger S, Pagliarini R, Chen Y, Zhou W. Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth. Oncotarget. 4: 2502-11. PMID 24318446 DOI: 10.18632/Oncotarget.1540  0.416
2013 Chen Y, Chen J, Loo A, Jaeger S, Bagdasarian L, Yu J, Chung F, Korn J, Ruddy D, Guo R, McLaughlin ME, Feng F, Zhu P, Stegmeier F, Pagliarini R, et al. Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. Oncotarget. 4: 816-29. PMID 23615731 DOI: 10.18632/Oncotarget.991  0.383
2013 Lin F, Saenz-Vash V, Zhai H, Fletcher J, Acker M, Jiang D, Gounarides J, Levell J, Pagliarini R. Abstract A20: IDH mutations and 2-HG selectively affect histone methylation in the endogenous setting Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-A20  0.362
2013 Grassian AR, Parker S, Davidson S, Green C, Lin F, Joud-Caldwell C, Yin H, Chung F, Straub C, Heiden MV, Pagliarini R, Metallo C. Abstract B159: Heterozygous IDH1 mutations modify the citric acid (TCA) cycle metabolism and sensitize cells to inhibition of mitochondrial respiration/oxidative phosphorylation. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B159  0.412
2012 Grassian AR, Lin F, Barrett R, Liu Y, Jiang W, Korpal M, Astley H, Gitterman D, Henley T, Howes R, Levell J, Korn JM, Pagliarini R. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). The Journal of Biological Chemistry. 287: 42180-94. PMID 23038259 DOI: 10.1074/Jbc.M112.417832  0.407
2012 Pagliarini RA. Abstract IA20: A bad influence: ERG, AR, and prostate cell differentiation Cancer Research. 72. DOI: 10.1158/1538-7445.Prca2012-Ia20  0.362
2010 Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Research. 70: 6804-14. PMID 20699365 DOI: 10.1158/0008-5472.Can-10-0409  0.454
2009 Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (New York, N.Y.). 325: 1555-9. PMID 19661383 DOI: 10.1126/Science.1174229  0.305
2009 Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Kinzler KW, Vogelstein B, Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proceedings of the National Academy of Sciences of the United States of America. 106: 3964-9. PMID 19225112 DOI: 10.1073/Pnas.0813333106  0.307
2007 Srivastava A, Pastor-Pareja JC, Igaki T, Pagliarini R, Xu T. Basement membrane remodeling is essential for Drosophila disc eversion and tumor invasion. Proceedings of the National Academy of Sciences of the United States of America. 104: 2721-6. PMID 17301221 DOI: 10.1073/Pnas.0611666104  0.576
2006 Igaki T, Pagliarini RA, Xu T. Loss of cell polarity drives tumor growth and invasion through JNK activation in Drosophila. Current Biology : Cb. 16: 1139-46. PMID 16753569 DOI: 10.1016/J.Cub.2006.04.042  0.551
2003 Pagliarini RA, Xu T. A genetic screen in Drosophila for metastatic behavior. Science (New York, N.Y.). 302: 1227-31. PMID 14551319 DOI: 10.1126/science.1088474  0.502
2003 Pagliarini RA, Quiñones AT, Xu T. Analyzing the function of tumor suppressor genes using a Drosophila model. Methods in Molecular Biology (Clifton, N.J.). 223: 349-82. PMID 12777740 DOI: 10.1385/1-59259-329-1:349  0.506
Show low-probability matches.